As some of the vaccine candidates have been given Emergency use Authorization (EUA), do we have the following clarity:

1. How many antibody values (titers) are protective?

2. What is average exposure (viral load) in routine clinical settings?

3. What is the required dose for various hyperimmune globulins under development and are they protective against new infections?

4. How much titer developed by the vaccine is said to protect from an infection? Any proof?

More Devang P Parikh's questions See All
Similar questions and discussions